Cargando…
Short-time interruption of second-line mycophenolate treatment in a patient with renal sarcoidosis enabled a marked antibody response to SARS-CoV-2 messenger RNA vaccine
Autores principales: | Schnuelle, Peter, Kölling, Sebastian, Müller, Alexander, Schmitt, Wilhelm H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862050/ https://www.ncbi.nlm.nih.gov/pubmed/35211315 http://dx.doi.org/10.1093/ckj/sfab289 |
Ejemplares similares
-
Extensive herpes zoster involvement following mycophenolate mofetil therapy for sarcoidosis
por: Hegde, Sandhya, et al.
Publicado: (2011) -
Nitric Oxide: The Coming of the Second Messenger*
por: Murad, Ferid
Publicado: (2011) -
Antioxidants and Second Messengers of Free Radicals
por: Zarkovic, Neven
Publicado: (2018) -
Mycophenolate mofetil as second line treatment in autoimmune hepatitis – A retrospective single center analysis
por: Kolev, Mirjam, et al.
Publicado: (2022) -
Tacrolimus and mycophenolate mofetil as second-line treatment in autoimmune hepatitis: Is the evidence of sufficient quality to develop recommendations?
por: Abdollahi, Mohammadreza, et al.
Publicado: (2020)